/
IPHYF
$1.65-$0.60 (-26.67%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$1.31 – $2.25
36% from low
Exchange
OTC Link
OS
Price (6 mo)
Loading chart…
Change$-2.70
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $79.9M | $69.0M | $69.8M | $12.1M | $49.6M | $61.6M | $12.6M | $2.8M |
| Cost of revenue | $69.6M | $45.2M | $49.7M | $47.0M | $51.7M | $56.0M | $52.0M | $0 |
| Gross profit | $10.3M | $23.8M | $20.1M | −$22.3M | $6.0M | $5.6M | $12.6M | $2.8M |
| Gross margin | 12.9% | 34.5% | 28.8% | -184.1% | 12.1% | 9.1% | 100.0% | 100.0% |
| R&D | $69.6M | $1.6M | $49.7M | $47.0M | $51.7M | $56.0M | $52.0M | $43.6M |
| Operating income | $5.1M | −$27.1M | $1.1M | −$47.8M | −$57.4M | −$12.7M | −$51.6M | −$53.4M |
| EBITDA | $12.5M | $18.1M | $13.3M | −$43.2M | −$12.3M | −$7.6M | −$46.9M | −$43.6M |
| Net income | $3.0M | −$20.8M | −$64.0M | −$52.8M | −$58.1M | −$7.6M | −$49.5M | −$49.2M |
| Net margin | 3.8% | -30.1% | -91.7% | -436.0% | -117.1% | -12.3% | -392.0% | -1764.5% |
| EPS (diluted) | 0.05 | -0.31 | -0.01 | -0.57 | -0.73 | -0.09 | -0.61 | -0.55 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $30M | $-0.24 | $-1.14–$0.04 | 1 |
| 2027 | $63M | $0.05 | $-0.01–$0.22 | 1 |
| 2028 | $40M | $-0.40 | $-1.85–$0.06 | 1 |
| 2029 | $185M | $0.33 | $-0.05–$1.54 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
INNATE PHARMA
INNATE PHARMA
Held by traders on TradeandTell
No one on the platform currently holds IPHYF.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in IPHYF as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IPHYF yet.